ReviewAmerican journal of medicine open2025
Hospital Care for Pregnant Persons With OUD Review.
Review in American journal of medicine open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Maternal control during prenatal oxycodone exposure: differential effects of voluntary versus involuntary self-administration on offspring substance use vulnerability in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opioid use disorder is increasingly prevalent among pregnant persons. Hospitalists and general obstetricians are uniquely positioned to treat pregnant persons with OUD, who may not otherwise be engaged in care. Pregnant people with OUD face stigma, discrimination, and fear of losing custody of their children. Providers should offer supportive and nonjudgmental care that is guided by the principles of harm reduction. All pregnant persons should be screened for OUD, diagnosed and treated accordingly. Medications for opioid use disorder (MOUD), methadone and buprenorphine, are safe in pregnancy and are gold standard treatment. Patients should be initiated or continued on MOUD during hospitalization. Pregnancy may increase metabolism of both buprenorphine and methadone, and therefore, dosages may need to be increased or given more frequently. Given the increase of high potency synthetic opioids, such as fentanyl, providers should be familiar with low-dose buprenorphine initiation or rapid methadone titration. Providers should monitor for opioid withdrawal and treat aggressively with MOUD and adjuvant medications. This may also require full agonists opioids. OUD treatment and support should continue into the post-partum period, a time of increased vulnerabilities to return to use, OUD recurrence, and overdose. Discharge planning should be family-centered, considering partners, their family, and the newborn. Social work and peer navigators should be engaged to help coordinate long-term outpatient resources including postpartum psychosocial support services such as substance use disorder treatment and relapse prevention programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.